论文部分内容阅读
目的:对阿托伐他汀治疗心肌梗死后无症状心衰患者的临床效果进行观察分析。方法:选取我院收治的78例心肌梗死后无症状心衰患者作为研究对象,以患者入院顺序为依据将其分为对照组(39例)与观察组(39例),两组患者在常规治疗基础上加用口服阿托伐他汀,其中对照组剂量为20mg/d,观察组剂量为40mg/d,给药时间共12个月并进行随访。结果:两组患者治疗后NT-proBNP水平、LVESD、LVEDD均降低,LVEF均升高,观察组患者治疗后NT-proBNP水平、LVESD、LVEDD、LVEF相较于对照组效果更为显著,差异具有统计学意义(P<0.05)。结论:阿托伐他汀治疗心肌梗死后无症状心衰疗效显著,能够有效改善患者心功能,具有较好的推广应用价值。
Objective: To observe and analyze the clinical effect of atorvastatin on patients with asymptomatic heart failure after myocardial infarction. Methods: Seventy-eight patients with asymptomatic heart failure after MI were enrolled in this study. Patients were divided into control group (n = 39) and observation group (n = 39) On the basis of treatment plus oral atorvastatin, which the control group dose of 20mg / d, the observation group dose of 40mg / d, the administration time of 12 months and were followed up. Results: The levels of NT-proBNP, LVESD and LVEDD were decreased and LVEF were higher in both groups after treatment. The levels of NT-proBNP, LVESD, LVEDD and LVEF in the observation group were more significant than those in the control group after treatment Statistical significance (P <0.05). Conclusion: Atorvastatin treatment of asymptomatic heart failure after myocardial infarction significant effect, can effectively improve the patient’s cardiac function, with good value for the promotion.